MARKET

ANL

ANL

Adlai Nortye Group Ltd
NASDAQ
10.52
-0.33
-3.04%
After Hours: 10.52 0 0.00% 19:30 11/12 EST
OPEN
10.62
PREV CLOSE
10.85
HIGH
10.79
LOW
10.22
VOLUME
130.65K
TURNOVER
--
52 WEEK HIGH
17.25
52 WEEK LOW
0.8786
MARKET CAP
677.47M
P/E (TTM)
-94.1808
1D
5D
1M
3M
1Y
5Y
1D
Joseph Pantginis Maintains Buy Rating and $20 Price Target on AN4005’s Durable Responses and Favorable Safety Profile
TipRanks · 3d ago
Weekly Report: what happened at ANL last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at ANL last week (1026-1030)?
Weekly Report · 11/02 09:20
Adlai Nortye’s AN4035 Secures Late-Breaking Oral Slot at EORTC-NCI-AACR Cancer Symposium
TipRanks · 10/28 10:36
Adlai Nortye Group Reveals Oral Presentation For AN4035 Program Update At the Upcoming 38th EORTC-NCI-AACR Symposium
Benzinga · 10/27 20:09
Weekly Report: what happened at ANL last week (1019-1023)?
Weekly Report · 10/26 09:20
Weekly Report: what happened at ANL last week (1012-1016)?
Weekly Report · 10/19 09:20
Analysts Offer Insights on Healthcare Companies: Opko Health (OPK) and Adlai Nortye Ltd. Sponsored ADR (ANL)
TipRanks · 10/15 16:30
More
About ANL
Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment.

Webull offers Adlai Nortye Group Ltd (ADR) stock information, including NASDAQ: ANL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANL stock methods without spending real money on the virtual paper trading platform.